For example, the use of anti-G-CSF or anti-Bv8/PROK2 antibodies has been demonstrated to enhance the efficacy of anti-VEGFR2 therapy, providing a more comprehensive approach to inhibition of tumor angiogenesis [259]. Here, PROK2 is linked to neoplasm.